Thus, another study aimed to develop a model for screening potential patients diagnosed with anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive juvenile dermatomyositis (JDM), taking into consideration the limited access to myositis-specific antibodies in many developing countries due to financial and technological challenges. Here, IFIH1 is linked to juvenile dermatomyositis.